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Background: Previously, we reported that menadione activated rat, native heme oxygenase-2 (HO-2) and human
recombinant heme oxygenase-2 selectively; it did not activate spleen, microsomal heme oxygenase-1. The purpose
of this study was to explore some structure–activity relationships of this activation and the idea that redox properties
may be an important aspect of menadione efficacy.
Methods: Heme oxygenase activity was determined in vitro using rat spleen and brain microsomes as the sources of
heme oxygenase-1 and −2, respectively, as well as recombinant, human heme oxygenase-2.
Results: Menadione analogs with bulky aliphatic groups at position-3, namely vitamins K1 and K2, were not able to
activate HO-2. In contrast, several compounds with similar bulky but less lipophilic moieties at position-2 (and −3) were
able to activate HO-2 many fold; these compounds included polar, rigid, furan-containing naphthoquinones,
furan-benzoxazine naphthoquinones, 2-(aminophenylphenyl)-3-piperidin-1-yl naphthoquinones. To explore the
idea that redox properties might be involved in menadione efficacy, we tested analogs such as 1,4-dimethoxy-2-
methylnaphthalene, pentafluoromenadione, monohalogenated naphthoquinones, α-tetralone and 1,4-naphthoquinone.
All of these compounds were inactive except for 1,4-naphthoquinone. Menadione activated full-length recombinant
human heme oxygenase-2 (FL-hHO-2) as effectively as rat brain enzyme, but it did not activate rat spleen
heme oxygenase.
Conclusions: These observations are consistent with the idea that naphthoquinones such as menadione bind to a
receptor in HO-2 and activate the enzyme through a mechanism that may involve redox properties.
Keywords: Heme oxygenase, Enzyme activator, Menadione, Agonist, In vitro, Redox propertiesBackground
Drug targets or drug receptors include a broad array of
cellular entities that range from receptors for intercellular
transmitters to ion channels to genetic macromolecules to
enzymes. Examples of the latter include xanthine oxidase,
aldehyde dehydrogenase, angiotensin converting enzyme
and acetylcholinesterase for which allopurinol, disulfuram,
enalaprilate and organophosphates, respectively, act as
ligands. In their 2010 review, Zorn and Wells [1] high-
light the observation that inhibition of enzyme function
is the usual modus operandi of drug discovery programs
that target specific enzymes; accordingly in all of the* Correspondence: nakatsuk@queensu.ca
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article, unless otherwise stated.examples given above the ligands inhibited the enzymes.
The pursuit of small molecules that activate enzymes is
much less common as is the number of therapeutic agents
that increase the activity of enzyme molecules.
In the realm of heme oxygenases (HO), much of the
progress made toward understanding their functional
roles has exploited animals that are genetically deficient
in either HO-1 or HO-2, treatments that induce HO-1,
or drugs that inhibit these enzymes [2,3]. Through
utilization of these tools, we now appreciate that heme
oxygenases and their products are involved in an in-
teresting array of cellular activities. For example, con-
siderable evidence revealed that HO-1 affords tissue
protection in the vasculature due to the antioxidant,
anti-inflammatory and anti-apoptotic properties of its
products (see review by Araujo et al. [4]). Similarly,entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Vukomanovic et al. Medical Gas Research 2014, 4:4 Page 2 of 11
http://www.medicalgasresearch.com/content/4/1/4there is substantial evidence that HO-1 protects neurons
against oxidative stress [5]. The first generation of HO
inhibitors comprises the metalloporphyrins, such as zinc
protoporphyrin (ZnPP) and tin protoporphyrin (SnPP),
which are powerful inhibitors of both HO-1 and HO-2
[6]. With respect to the cardiovascular system, Araujo
et al. [4] have reviewed the evidence showing that HO-1 is
protective against vascular inflammation, and cite exam-
ples such as the worsening of ischemia reperfusion injury
in the presence of ZnPP [7]. Our laboratory has subse-
quently created a series of azole-based HO inhibitors,
many of which are selective for HO-1 [8,9] and more
recently a series of compounds that are selective for
HO-2 [10]. As was the case for research addressing
enzymes as drug targets in general, virtually all of the
literature on small molecules that affect heme oxygenases
was devoted to inhibitors of these enzymes. An exception
to this was our recent report on the in vitro activation of
HO-2 by menadione [11]. Menadione activated both the
rat, native HO-2 and recombinant human HO-2 seven to
thirty-fold, and did not activate HO-1. The mechanism of
activation of HO-2 was through an increase in maximum
velocity and not by a change in affinity for the substrate.
In this communication, we present some structure–
activity relationships of menadione and its analogs as
activators of HO-2, and test the hypothesis that redox
properties of these compounds participate in their acti-
vation of HO-2.
Methods
Native HO-1 and HO-2 were prepared as microsomes
from rat spleen and brain as described previously by
Vukomanovic et al. [11]. All animals used were cared for
in accordance with the principles and guidelines of the
Canadian Council on Animal Care and the experimental
protocols were approved by the Queen’s University Animal
Care Committee. A full-length cDNA clone of full-length
human HO-2 (FL-hHO-2) in pOTB7 was obtained from
Open Biosystems. Following PCR amplification to engin-
eer NdeI and EcoRI sites at the 5’ and 3’ ends, respectively,
the coding region was subcloned into the pET28a vector
using these restriction sites. The resultant recombinant
protein contained an N-terminal histidine tag to allow
purification by metal chelation using a protocol modified
from previous publications [12,13]. Briefly, BL21 (DE3)
cells, transformed with the FL-hHO-2/pET28a plasmid,
were grown in LB supplemented with 30 μg/mL of
kanamycin at 37°C until an OD600 of ~ 0.8, at which
point protein expression was induced with 1 mM iso-
propyl β-D-1-thiogalactopyranoside. Cells were grown
for a further 3–4 h before harvesting and cell pellets
were stored at −80°C until ready to purify. Subsequently,
thawed pellets were resuspended in lysis buffer [50 mM
NaH2PO4 (pH 8.0), 300 mM NaCl, lysozyme (0.5 mg/mL;BioShop), DNaseI (5 units/mL; Fermentas), EDTA-free
protease inhibitor cocktail (1 tablet/50 mL; Roche)], incu-
bated on ice (30 min) and lysed by sonication. Following
centrifugation at 27,000 × g (15,000 rpm in a Beckman JA
25.5 rotor), the resultant pellets were solubilized in lysis
buffer containing 1% n-Dodecyl β-D-Maltopyranoside
(Affymetrix) overnight at 4°C. Solubilized protein was col-
lected from the supernatant following centrifugation at
31,000 × g (16,000 rpm in a Beckman JA 25.5 rotor) and
combined with the previously clarified lysate for purifi-
cation by nickel affinity chromatography using Ni-NTA
agarose resin. The combined supernatants were allowed
to bind to the resin by rocking for 1 h at 4°C. After
collecting the flowthrough, unbound protein was re-
moved by a step-wise imidazole gradient (0–50 mM);
protein was eluted by an addition step-wise gradient from
100–500 mM imidazole. Protein-containing fractions
were identified by 12% SDS-PAGE and positive frac-
tions (200–500 mM) dialyzed overnight against 20 mM
potassium phosphate (pH 7.4), 0.1 mM EDTA, 10%
glycerol. Following protein quantification (Bio-Rad), heme
was conjugated by slow addition of hemin solution to
a final molar ratio of 2:1 as described previously by
Rahman et al. [13]. Further purification of the heme-
bound enzyme and removal of excess heme was per-
formed by size-exclusion chromatography over an S200
column. Protein concentration was determined by ab-
sorbance (ε405 = 171.4 ± 1.2 mM
-1 cm-1) [13]. Purity was
assessed by measurement of the Rz ratio (A405/A280 > 2.1)
and by SDS-PAGE analysis.
HO-1 and HO-2 activities were determined as described
by Vukomanovic et al. [11]. In brief, a reaction mixture
(150 μL) containing 100 mM phosphate buffer (pH 7.4),
50 μM methemalbumin and 0.5 mg mL-1 brain or
1 mg mL-1 spleen protein was pre-incubated with an HO
activator, concentration as described below, for 10 min at
37°C. Methemalbumin was prepared by dissolving hemin
in 10% (w/v) ethanolamine in water, and mixing it with a
bovine serum albumin that had been dissolved in water
[14,15]. The reaction was initiated by adding 1 mM
NADPH and was continued for 15 min at 37°C. The re-
action was stopped by instantly freezing the reaction
mixture on dry ice, and the generated CO was deter-
mined by gas chromatography. For experiments involving
FL-hHO-2, the concentration of the enzyme was 0.7 μM
and the concentration of purified human NADPH-P450
reductase (recombinant, Becton Dickinson Canada Inc.,
Toronto, ON, Canada) was 0.01 μM.
Source of drugs
Drugs and compounds were obtained from the following
sources: Sigma-Aldrich (Toronto, ON, Canada)- mena-
dione, vitamin K2, NADPH, bovine serum albumin,
hemin and L-ascorbic acid; Alfa Aesar- (A Johnson
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Chemical Industry America (Portland, OR, USA)- hydro-
quinone, 1,4-benzoquinone, and 1,4-naphthoquinone (1,4-
naphthalenedione); Acros Organics (Fair Lawn, NJ,
USA)- alpha-tetralone, 1,4-cyclohexanedione; Ryan Scientific
(Mt. Pleasant, SC, USA)- pentafluoromenadione; Otava
Ltd. (Toronto, ON, Canada)- furan-containing naphtho-
quinones, furan-benzoxazine containing naphthoquinones,






















































Figure 1 Lack of effect of vitamins K1 and K2 on HO-1 and HO-2 activ
Methods using spleen (solid triangles) and brain (open circles) microsomes
shows HO-2 activity as a percent of control in the absence of added drug.
K1 and K2 in the panels to illustrate their differences from menadione.naphtoquionones. 2-Phenylnaphthoquinones were obtained
from Snieckus Innovations (Kingston, ON, Canada).
1,4-Dimethoxy-2-methylnaphthalene (methoxy analog of
menadione) was a gift from Dr. D. N. Criddle, University
of Liverpool, UK.
Results
An important biological property of menadione is its
activity as a K vitamin; thus, we were interested to know-6 -5 -4 -3
H O -1
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ity in vitro. HO-1 and HO-2 activity were measured as described in
, respectively. The abscissa shows drug concentration and ordinate
Panel a, Vitamin K1 and panel b, Vitamin K2. The structures of vitamins
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contrast to menadione, neither vitamin K1 nor vitamin
K2 was able to increase the enzymatic activity of either
HO-1 or HO-2 as shown in Figure 1. Thus, the HO-1
and HO-2 activity curves for vitamin K1 (panel a) were
flat from 10 nM to10 μM with a small upward trend at
100 μM for brain microsomal HO-2, and the curves for
vitamin K2 (panel b) were flat throughout the full con-
centration range. In comparison, menadione activated
HO-2 about 7-fold (Figure 2). Structurally menadione
differs from vitamins K1 and K2 in that it possesses a
methyl moiety at the 2-position whereas vitamins K1 and
K2 each possess an additional, adjacent long unsaturated
aliphatic side chain (Figure 1). Because this side chain
could possibly interfere with binding of vitamin K1 or K2
to HO-2 through steric hindrance, we decided to explore
the activity of other menadione analogs that possessed
large non-aliphatic substituents at positions-2 and −3.
For these experiments, we tested menadione analogs that
possessed various substituents at the 2- and 3-positions
including- naphthoquinones containing furan-carboxylic
acid substituents (Table 1), naphthoquinones containing
furan-benzoxazine (Table 2), naphthoquinones contain-
ing aminophenyl and piperidinyl moieties (Table 3),
naphthoquinones containing 2-phenyl (Table 4) and
other naphthoquinones containing various substituents
at positions-2 and −3 (Table 5). Tables 1, 2, 3 and 4





























Figure 2 Activation of rat brain HO-2 by menadione, and lack of activ
(5 F-MD). HO-1 and HO-2 activity were measured as described in Methods
drug concentration and the ordinate shows HO activity as a percent of con
activation of HO-2, and solid triangles show lack of activation of rat spleen
analog of menadione. Open triangles show lack of activation of HO-2 by thanalogs possessing a wide variety of substituents at the
2- and 3-position. For example, compound 71830417
(a furan-containing naphthoquinone) activated HO-2 to
693% of control, SI-859 (a 2-phenylnaphthoquinone) acti-
vated HO-2 to 691%, and 7010100237 (a 2-(aminophenyl)-
3-piperidin-1-yl)naphthoquinone) activated HO-2 to 249%
of control. Clearly, a variety of moieties could be present
at the 2- and 3-positions of naphthoquinone, with main-
tenance of the ability to activate HO-2. Thus, unlike vita-
mins K1 and K2, the mere presence of a large substituent
at the 2- and 3-positions in these compounds did not
render them unable to activate HO-2.
Mechanism of action
According to classical receptor theory, an agonist drug
such as menadione possesses affinity for its receptor on
HO-2 and efficacy once it has bound. The inactivity of
vitamin K1 might be explained by an inability to bind to
HO-2. To explore this, we tested the effects of menadione
in the presence of vitamin K1. This experiment was done
in two ways- by adding vitamin K1 (10 – 100 μM) to the
reaction mixture before menadione (25 μM) or after
menadione. Both iterations yielded no effect on mena-
dione activation of HO-2; vitamin K1 did not alter the
menadione-induced activation of HO-2 (data not shown).
An obvious characteristic of menadione and its analogs
studied herein is their naphthoquinone core, which is
known to participate in redox reactions [16]. Consequently,-5 -4 -3
M D /H O -1
ru g ]















ation by dimethoxymenadione (DMD) and pentafluromenadione
using spleen and brain microsomes, respectively. The abscissa shows
trol in the absence of added drug. Open circles show menadione
HO-1. Solid circles show lack of activation of HO-2 by dimethoxy
e fluoro analog of menadione.
Table 1 HO-2 activation by naphthoquinones containing furan-carboxylic acid substituents
Structure HO-2 HO-1 Structure HO-2 HO-1



































Rat HO-1 and HO-2 activities were determined as described in Methods. Test compounds were used at a concentration of 100 μM. Activity is reported as a
percentage of activity in the absence of test compound; control = 100%. The 10-digit numbers are Otava catalog numbers.
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activity was compromised to determine if there was a
direct correlation between redox properties and acti-
vation of HO-2. One such analog was 1,4-dimethoxy-
2-methylnaphthalene wherein the keto oxygens of
menadione are replaced by methoxy groups; thisanalog did not activate HO-2 as shown in Figure 2.
Another analog used was pentafluoromenadione, which
would be compromised in redox reactions due to the
strong electron-withdrawing action of the five fluorine
atoms; pentafluoromenadione was without HO-2 stimu-
lating activity (Figure 2). Table 6 shows the lack of
Table 2 HO-2 activation by naphthoquinones containing furan-benzoxazine moieties
Structure HO-2 HO-1 Structure HO-2 HO-1

















Rat HO-1 and HO-2 activities were determined as described in Methods. Test compounds were used at a concentration of 100 μM. Activity is reported as a
percentage of activity in the absence of test compound; control = 100%. The 10-digit numbers are Otava catalog numbers.
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http://www.medicalgasresearch.com/content/4/1/4activation of HO-2 by 2-bromo-5-hydroxynaphthoquinone
and 2-chloro-3-hydroxynaphthoquinone. To explore fur-
ther the relationship between redox properties and activa-
tion of HO-2, we tested two series of benzoquinone- and
naphthoquinone-like molecules as shown in Table 7.
Thus, within the triad of 1,4-cyclohexanedione, hydro-
quinone and 1,4-benzoquinone, there was a majorTable 3 HO-2 activation by naphthoquinones containing amin
Structure HO-2 HO-1





Rat HO-1 and HO-2 activities were determined as described in Methods. Test comp
percentage of activity in the absence of test compound; control = 100%. The 10-digdifference in effect on HO-2 activity. Those compounds
that were poor candidates for redox activity, namely
1,4-cyclohexanedione and hydroquinone, were essentially
inactive toward both HO-1 and HO-2. Meanwhile 1,4-
benzoquinone did not activate HO-2, but was a strong
inhibitor of both HO-1 and HO-2. Of the α-tetralone
and 1,4-naphthoquinone pair, α-tetralone was inactiveophenyl-piperidinyl substituents
Structure HO-2 HO-1





ounds were used at a concentration of 100 μM. Activity is reported as a
it numbers are Otava catalog numbers.
Table 4 HO-2 activation by naphthoquinones containing 2-phenyl moieties
Structure HO-2 HO-1 Structure HO-2 HO-1















HO-1 and HO-2 activities were determined as described in Methods. Test compounds were used at a concentration of 100 μM. Activity is reported as a percentage
of activity in the absence of test compound; control = 100%. MOMO is methoxymethyl ether. SI = Sniekus Innovations.
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little effect on HO-1, but activated HO-2 five-fold.Menadione activation of recombinant human HO-2
Our drug design work has relied heavily on the rat, native
HOs, in part because the native enzymes were crucial in
allowing us to create selective inhibitors of HO-1 [11].
Nevertheless, the ultimate application of knowledge to
human health requires one to explore the novel effects of
drugs in the human context. Furthermore, working with a
purified recombinant protein sample provides insights at
the molecular level that is often challenging when using a
mixture. Accordingly, we tested the effects of menadione
on recombinant human HO-2. Figure 3 shows that the
FL-hHO-2, was activated ~7-fold by menadione, whichcompares well with menadione-activation of the rat, native
HO-2 (also ~ 7-fold).
Discussion
The goals of this work were to explore the structure-
activity relationship of menadione activation of HO-2
and to test the hypothesis that redox properties of mena-
dione and its analogs participate in their activation of
heme oxygenase-2. The main observations made in the
present study were- (a) HO-2 was not activated by vita-
mins K1 and K2 but was activated by menadione (vitamin
K3), (b) HO-2 was activated by furan carboxylic acid-
containing naphthoquinones, furan-benzoxazine-containing
naphthoquinones, 2-phenylnaphthoquinones, and 2-
(aminophenyl)-3-(piperidin-1-yl)naphthoquinones, (c) the
dimethoxy, pentafluoro and monohalogenated analogs of
Table 5 Lesser HO-2 activation by naphthoquinones
containing various additional moieties
Structure HO-2 HO-1 Structure HO-2 HO-1























HO-1 and HO-2 activities were determined as described in Methods. Test compounds were used at a concentration of 100 μM. Activity is reported as a percentage
of activity in the absence of test compound; control = 100%. The 10-digit numbers are Otava catalog numbers.
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strongly activated HO-2, and (e) full-length human re-
combinant HO-2 was activated to a similar extent as
rat, native HO-2.
The absence of HO-2 activation by vitamins K1 and K2
indicates that the receptor responsible for HO-2 activa-
tion by menadione differs from the receptor for vitamin
K activity. As stated above, this lack of HO-2 activation
by vitamins K1 and K2 could have been due to their
bulky aliphatic side chains sterically hindering binding
to the enzyme or lack of inducing an appropriateactivating conformational change of HO-2. The obser-
vation that addition of both menadione and vitamin
K1 to the in vitro reaction mixture resulted in activa-
tion of HO-2 similar to that of menadione alone is
consistent with the notion that vitamin K1 does not
bind to the same site on HO-2 as does menadione.
Had vitamin K1 bound to the menadione binding site,
it would have antagonized the activating effect of
menadione. Nevertheless, we acknowledge the fact that
binding experiments with a radiolabelled ligand were
not conducted.
Table 6 Monohalogenated, monohydroxynaphthoquinones are inactive as HO activators
Structure HO-2 HO-1 Structure HO-2 HO-1





HO-1 and HO-2 activities were determined as described in Methods. Test compounds were used at a concentration of 100 μM. Activity is reported as a
percentage of activity in the absence of test compound; control = 100%. The 10-digit number is an Otava catalog number; SI = Sniekus Innovations.
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http://www.medicalgasresearch.com/content/4/1/4This inability of vitamin K1 to bind to the menadione
binding site on HO-2 does not appear to be due to steric
hindrance alone because the side chains attached to the
compounds listed in Tables 1, 2, 3, 4 are similar in size
to the aliphatic side chains of vitamin K1. While these
compounds are similar to vitamins K1 and K2 with respect
to the presence of a significantly large moiety at carbon-2,
they differ substantially in the nature of the substituent;
these compounds contain hetero-atoms that wouldTable 7 HO activity in the presence of benzoquinone-like and










HO-1 and HO-2 activities were determined as described in Methods. Test compoun
of activity in the absence of test compound; control = 100%.increase polarity. If there are polar sites on HO-2 in
the region of the menadione binding site, they might
be compatible with heteroatom-containing side chains
but incompatible with non-polar moieties such as the
aliphatic side chain of vitamin K1.
The hypothesis that redox properties of menadione
and its analogs participate in their activation of HO-2
arose from the well-known redox properties of the quin-
one nucleus [16]. Our observation that the dimethoxynaphthoquinone-like compounds








ds were used at a concentration of 100 μM. Activity is reported as a percentage
























Figure 3 Menadione activated full-length human, recombinant
HO-2 similar to rat native HO-2. HO-2 activity was measured as
described in Methods using recombinant hHO-2 (open circles) and rat
brain microsomes (closed triangles) as the source of HO-2. The abscissa
shows drug concentration and ordinate shows HO-2 activity as a
percent of control in the absence of added drug (mean ± SD, n = 4).
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was unable to activate HO-2 is consistent with the hypoth-
esis. In the case of 1,4-dimethoxy-2-methylnaphthalene,
the absence of the quinone nucleus would block the
ability of this molecule to participate in redox reactions
[17]. In the case of pentafluoromenadione, the presence
of the five fluorine atoms causes a large change in the
behaviour of electrons (negative inductive effect) of the
naphthoquinone nucleus; accordingly, the reduction po-
tential of pentafluoromenadione would be in the order of
400 mV compared with −203 mV for menadione [18].
This reduction potential for the pentafluorinated analog
of menadione would obviate redox function. Further
support for this line of reasoning may be found in the
lack of HO-2 activation by the two monohalogenated,
monohydroxy naphthoquinone analogs shown in Table 6,
which were found not to activate either HO-2 or HO-1.
The hydroxyl groups on the latter two molecules could
also contribute to this loss of HO-2 activation through
resonance-based decreases in redox reactions. The HO-2
data obtained with these four compounds are consistent
with the hypothesis as articulated above.
Another approach taken was to test the effects
of five commercially available benzoquinone-like and
naphthoquinone-like compounds on HO activation as
shown in Table 7. Based on their chemical structures,
we considered the hypothesis to predict that α-tetralone
would be a poor activator of HO-2 because it would
not be active with respect to redox activity. Similarly,
1,4-cyclohexanedione and hydroquinone were predicted
to be inactive as HO-2 activators. The hypothesis pre-
dicted that 1,4-naphthoquinone would be fully active as
an HO-2 activator because it possesses the completequinone nucleus that is essential for redox reactions.
While 1,4-benzoquincbone shares a quinone nucleus with
1,4-naphthoquinone, it was anticipated to be inactive
because it has been observed not to participate in redox
reactions but rather it arylates protein thiols [19]. Thus,
the data obtained from these five compounds are consist-
ent with the hypothesis articulated above. On balance, it
appears that HO-2 activating naphthoquinones require
both affinity for a selective receptor and redox activity.
The observations that these naphthoquinones activated
HO-2 but did not activate HO-1 are interesting from both
mechanistic and application perspectives; certainly they
should be useful for elucidating the roles of HO-1 and
HO-2 in various physiological and metabolic functions.
This observation also indicates that these HO-2 activators
bind to a site on HO-2 other than the catalytic site be-
cause of the high conservation of amino acid sequence
between HO-1 and HO-2 therein. We have excluded
cytochrome P450 reductase as the activation site by ob-
serving that hHO-2 (1–288) activation occurred (>200%)
in the absence of NADPH and cytochrome P450 reduc-
tase whereby the source of reducing capacity was ascorbic
acid (data not shown). In the present experiments, the
source of reducing equivalents would include NADPH. In
the case of enzyme inhibitors the locus of drug binding is
often at or near the active site, as would be the case for
competitive inhibitors. In the case of enzyme activators,
the binding site should not be the same as that of the
natural substrate (i.e. active site), because binding of a
non-substrate molecule there must result in competi-
tive inhibition. It follows that an enzyme activator must
bind beyond the active site, but still influence the reaction
in a positive manner.
Conclusions
The activation of HO-2 by menadione and similar ago-
nists requires affinity for a receptor site outside of the
enzyme core (which it shares with HO-1) and probably
also the ability to participate in redox reactions.
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